Cochlear Shares Continue to Bounce Off Decade Lows, As Analyst Trims Target

Cochlear shares (ASX: COH) have put holders through the ringer this year, continuing to sit 59% lower YTD, despite a 20% bounce from their recent decade. With the share price having built some momentum off the low of A$88.74 to close at A$106.86, the longer-term bear trend remains firmly visible on the 1 year chart below, as bulls look to shift the tide.

Today’s 2.31% gain for Cochlear came as UBS cut it’s earnings forecasts, trimming its price target to A$106 from A$109 while maintaining a Neutral rating.

What has been driving the Cochlear share price?

The share price recovery from multi-year lows comes amid a challenging operating environment for the medical device company, with UBS analysts citing Middle East geopolitical exposure, persistent US payer pressures, and operational stumbles across Western Europe as key factors behind the 2-3% reduction in FY26-27 earnings forecasts. The broker’s revised A$106 target now sits in line with current trading levels, suggesting limited near-term upside under base-case assumptions.

UBS identifies the Middle East as the critical swing factor for Cochlear’s FY26 performance, with the Iran conflict expected to push outcomes toward the higher end of the company’s internal risk range. This geopolitical uncertainty has driven the 2% cut to FY26 net profit after tax forecasts, as regional instability disrupts healthcare budgets and delays capital equipment procurement decisions across key markets. However, UBS emphasises that the sales impact should be viewed as delayed rather than permanently lost, potentially providing support for FY27 revenues once conditions stabilise.

The broker expects Cochlear to issue cautious FY27 guidance featuring a relatively wide profit range, with the midpoint likely sitting below current consensus estimates. This suggests further downward earnings revisions may be ahead as the market recalibrates expectations for the hearing implant leader’s medium-term growth trajectory.

In the United States, UBS channel checks reveal a mixed picture. Patient volumes have not experienced a sharp drop, indicating underlying demand remains intact, but persistent payer pressure (particularly Medicare Advantage denials), and softer referral flow are creating headwinds. The Medicare Advantage denial issue has become a broader concern across the US medical device sector, as cost-containment measures by government-linked insurance plans increasingly delay or prevent procedures despite clinical need.

Western European weakness appears tied to operational execution issues across multiple large markets rather than fundamental demand deterioration, according to UBS. The broker expects these market share losses to be cycled over time as the company addresses internal process, distribution, and staffing challenges. This characterisation suggests the problems are fixable rather than structural, though execution risk remains elevated given the simultaneous nature of issues across several major European economies.

The 20% bounce from decade lows indicates capitulation selling may have run its course in the near term, with some viewing the stock as oversold relative to its long-term structural position in the global hearing implant market. Yet there remains plenty of work to do in order to shift momentum more meaningfully, with a move above the 50 day moving average, currently at $114, a near term target for bulls.